@article{oai:repo.qst.go.jp:00045565,
 author = {Tsujii, Hirohiko and Mizoe, Junetsu and Kamada, Tadashi and Baba, Masayuki and Tsuji, Hiroshi and Katou, Hirotoshi and Kato, Shingo and Yamada, Shigeru and Yasuda, Shigeo and Ohno, Tatsuya and Yanagi, Takeshi and Imai, Reiko and Kagei, Kenji and Kato, Hiroyuki and Hara, Ryusuke and Hasegawa, Azusa and Nakajima, Mio and Sugane, Toshio and Takagi, Ryo and Tamaki, Tomoaki and Kandatsu, Susumu and Yoshikawa, Kyosan and Kishimoto, Riwa and Miyamoto, Tadaaki and 辻井 博彦 and 溝江 純悦 and 鎌田 正 and 馬場 雅行 and 辻 比呂志 and 加藤 博敏 and 加藤 眞吾 and 山田 滋 and 安田 茂雄 and 大野 達也 and 柳 剛 and 今井 礼子 and 影井 兼司 and 加藤 弘之 and 原 竜介 and 長谷川 安都佐 and 中嶋 美緒 and 須金 紀雄 and 高木 亮 and 田巻 倫明 and 神立 進 and 吉川 京燦 and 岸本 理和 and 宮本 忠昭},
 issue = {Suppl.A},
 journal = {Journal of Radiation Research},
 month = {Mar},
 note = {Carbon ions/Charged particles/Dose distribution/RBE/Clinical study.
In 1994 a Phase I/II clinical study on carbon ion radiotherapy was begun at NIRS using HIMAC, which was then the world’s only heavy ion accelerator complex dedicated to medical use in a hospital environment. Among several types of ion species, we have chosen carbon ions for cancer therapy because they had the most optimal properties in terms of possessing, both physically and biologically, the most effective dose-localization in the body. The purpose of the clinical study was to investigate the efficacy of carbon ion radiotherapy against a variety of tumors as well as to develop effective techniques
for delivering an efficient dose to the tumor. The RBE of carbon ions was estimated to be 2.0 to 3.0 along the SOBP for acute skin reactions. As of August 2006, a total of 2,867 patients had been entered into Phase I/II or Phase II studies and analyzed for toxicity and local tumor response. The results have shown that carbon ion radiotherapy has the potential ability to provide a sufficient dose to the tumor with acceptable morbidity in the surrounding normal tissues. Tumors that appear to respond favorably to carbon ions include locally advanced tumors and those with histologically non-squamous cell type of tumors such as adenocarcinoma, adenoid cystic carcinoma, malignant melanoma, hepatoma, and bone/soft tissue sarcoma. By taking advantage of the biological and physical properties of high-LET radiation,
the efficacy of treatment regimens with small fractions in short treatment times has been confirmed for almost all types of tumors in carbon ion radiotherapy.},
 pages = {A1--A13},
 title = {Clinical Results of Carbon Ion Radiotherapy at NIRS},
 volume = {48},
 year = {2007}
}